The review concluded that for patients with stable coronary artery disease and objectively documented myocardial ischaemia, percutaneous coronary intervention with medical therapy was not associated with a reduction in death, nonfatal myocardial infarction, unplanned revascularisation or angina compared with medical therapy alone. The authors' conclusions reflect the evidence presented and seem reliable for the primary outcome of interest.
Study selection
Eligible were randomised controlled trials (RCTs) that compared percutaneous coronary interventions and medical therapy against medical therapy alone. Eligible patients had stable coronary artery disease. Included studies had to have stent implantation in at least 50% of percutaneous coronary intervention procedures and statin medications in at least 50% of patients in both percutaneous coronary intervention and medical therapy arms. Trials had to report the outcomes of death and nonfatal myocardial infarction. Myocardial ischaemia or abnormal fractional flow reserve had to be documented in some or all patients prior to randomisation. Trials of stable patients following a completed myocardial infarction were excluded.
Medical therapy included aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and statins. All studies allowed crossover from medical therapy to percutaneous coronary intervention for intolerable symptoms. Two studies used drug-eluting stents in 37% and 95% of patients. Stress testing varied between studies. From 62% to 100% of the participants were men. From 22% to 100% of participants had diabetes and from 25% to 40% had a prior myocardial infarction. Mean ejection fractions ranged from 57% to 69%. The extent of coronary artery disease ranged from single-vessel to three-vessel disease. Stents were implanted in 66% to 100% of patients. Outcomes assessed included death from any cause, nonfatal myocardial infarction (variably defined), unplanned revascularisation (percutaneous coronary intervention or coronary artery bypass graft) and angina. Studies were conducted in Brazil, North America and Europe.
The authors did not state how many reviewers selected studies for inclusion.
Assessment of study quality
Study quality was assessed using Jadad criteria of randomisation, blinding and withdrawals. It appeared that two reviewers independently assessed study quality.
Data extraction
Two reviewers independently extracted outcome data for all patients who had documented either myocardial ischaemia on stress testing or an abnormal fractional flow reserve. In the case of no events recorded, a nominal amount of 0.5 cases was added to the results for both groups. Intention-to-treat data were used to calculate odds ratios and 95% confidence intervals. Data were extracted at the longest follow-up period for each outcome up to a maximum of five years. Primary study authors were contacted for missing data (including unpublished data and data on subsets of patients with ischaemia at the time of randomisation in studies where not all were required to have ischaemia on stress testing). 
Methods of synthesis
Pooled odds ratios and 95% confidence intervals were calculated using the inverse variance method with a randomeffects model. Statistical heterogeneity was assessed using the Q and Ι² tests. Subgroup analyses were prespecified and performed based on the requirement of ischaemia for trial entry versus no requirement for ischaemia at trial entry and for trials that enrolled patients prior to 2000 versus enrolment after 2000. Sensitivity analyses were conducted for each outcome, removing individual trials one at a time. Publication bias was assessed using a funnel plot and the Egger test.
Results of the review
Five RCTs were included in the review (4,064 participants with ischaemia at randomisation, range 101 to 1,938). All trials reported random assignment and reported withdrawal descriptions. No trials reported blinding. Follow-up ranged from 231 days to five years.
There were no significant differences between treatment with percutaneous coronary interventions with medical therapy or medical therapy alone for patients with stable coronary artery disease and objectively documented myocardial ischaemia for death (OR 0.90, 95% CI 0.71 to 1.16), nonfatal myocardial infarction (OR 1.24, 95% CI 0.99 to 1.56), unplanned revascularisation (OR 0.64, 95% CI 0.35 to 1.17) and recurrent or persistent angina (OR 0.91, 95% CI 0.57 to 1.44). There was evidence of heterogeneity for the analyses of unplanned revascularisation (Ι²=90%) and angina (Ι²=72%). Results of subgroup analyses did not significantly alter the results.
Removal of one trial resulted in a statistically significant reduction in the number of unplanned revascularisations in favour of the percutaneous coronary intervention group compared to medical therapy (OR 0.49, 0.26 to 0.91). The remaining sensitivity analyses did not significantly change the overall results. There was no evidence of publication bias.
